Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Persistent mutations render cancer cells susceptible to immunotherapy

Tumor mutation burden is an imperfect predictor of response to immunotherapies. Mutations in regions of the genome unlikely to undergo loss during tumor evolution constitute a persistent tumor mutation burden that may drive sustained immunological tumor control in the context of cancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: pTMB and response to immune checkpoint blockade.


  1. Anagnostou, V. et al. Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. Sci. Trans. Med. 14, eabo3958 (2022). A comprehensive review article that discusses the development of predictive biomarkers for cancer immunotherapy.

    Article  CAS  Google Scholar 

  2. Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Gen. 51, 202–206 (2019). This paper evaluates the context-specific association between TMB and clinical outcomes with immune checkpoint inhibition.

    Article  CAS  Google Scholar 

  3. Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596–614.e14 (2021). This paper reports a meta-analysis of molecular determinants of response to immune checkpoint inhibition.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer. Cancer Discov. 7, 264–276 (2017). This paper reported loss of mutation-associated neoantigens as a mechanism of acquired resistance to immune checkpoint inhibition.

    Article  CAS  PubMed  Google Scholar 

  5. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014). This paper reported the role of tumor-specific mutant neoepitopes as targets of T cell responses during immune checkpoint blockade.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Niknafs, N. et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat. Med. (2023).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Persistent mutations render cancer cells susceptible to immunotherapy. Nat Med 29, 311–312 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer